GASTROINTESTINAL STROMAL TUMOR (GIST)
Clinical trials for GASTROINTESTINAL STROMAL TUMOR (GIST) explained in plain language.
Never miss a new study
Get alerted when new GASTROINTESTINAL STROMAL TUMOR (GIST) trials appear
Sign up with your email to follow new studies for GASTROINTESTINAL STROMAL TUMOR (GIST), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for GIST: experimental drug DCC-3009 enters human trials
Disease control Recruiting nowThis study tests a new drug called DCC-3009, alone or with other cancer treatments, for people with advanced GIST that has stopped responding to standard therapy. The trial has two parts: first, finding a safe dose, then checking if the drug shrinks tumors. About 120 participants…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 16, 2026 22:34 UTC
-
New hope for Hard-to-Treat GIST: oral combo trial launches
Disease control Recruiting nowThis study tests a new oral drug, ziftomenib, combined with the standard drug imatinib in adults with advanced gastrointestinal stromal tumors (GIST) that no longer respond to imatinib alone. The goal is to see if the combination is safe and can shrink or stabilize tumors. About …
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 16, 2026 22:32 UTC
-
New hope for Hard-to-Treat gut tumors: first human trial launches
Disease control Recruiting nowThis study is the first time IDRX-42 is being tested in people. It is for adults with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tum…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: IDRX, Inc., a wholly owned subsidiary of GSK, LLC • Aim: Disease control
Last updated May 16, 2026 22:27 UTC
-
New pill HQP1351 enters human testing for hard-to-treat stomach and solid tumors
Disease control Recruiting nowThis early-phase study tests an oral drug called HQP1351 in about 100 people with advanced GIST (a type of stomach tumor) or other solid tumors. The main goal is to find a safe dose and see how the body processes the drug. Researchers will also watch for any signs that the drug s…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Stanford researchers dig into genetic roots of stomach and esophageal cancers
Knowledge-focused Recruiting nowThis study collects tissue and blood samples from people with stomach or esophageal cancer, as well as those at high inherited risk, to learn how genes and proteins contribute to these cancers. Researchers aim to better understand the disease, not to test a new treatment. About 1…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated May 16, 2026 22:32 UTC
-
NIH launches Long-Term GIST study to unlock tumor secrets
Knowledge-focused Recruiting nowThis study follows 400 people with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and then for 5 years after. The goal is to better understand the dise…
Matched conditions: GASTROINTESTINAL STROMAL TUMOR (GIST)
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 14, 2026 12:05 UTC